🔎 Trials Near Me

Hjem › Akut myelogen leukemi › Indiana

Kliniske studier for Akut myelogen leukemi i Indiana

14 studier for Akut myelogen leukemi søker deltakere på steder i Indiana.

Byer i Indiana

Offisiell studietekst (engelsk)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Reid Health, Richmond
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • UChicago Medicine Northwest Indiana, Crown Point
RekruttererFase 2
Alder 18 til 59 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT05554393

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT05564390

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

  • Clinical Trial Site, Indianapolis
RekruttererFase 3
Alder 12 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07211958

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • UChicago Medicine Northwest Indiana, Crown Point
  • Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  • UChicago Medicine Northwest Indiana, Crown Point
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • UChicago Medicine Northwest Indiana, Crown Point
  • Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
RekruttererFase 2
Alder 18 til 59 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Riley Hospital for Children, Indianapolis
  • Ascension Saint Vincent Indianapolis Hospital, Indianapolis
RekruttererFase 3
6 Months – 21 Years · Alle kjønn · Oppdatert 17. sep. 2026 · NCT04293562

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Riley Hospital for Children, Indianapolis
  • Ascension Saint Vincent Indianapolis Hospital, Indianapolis
RekruttererFase 1/2
Opp til 22 år · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  • Indiana University School of Medicine, Indianapolis
RekruttererFase 3
29 Days – 21 Years · Alle kjønn · Oppdatert 24. aug. 2026 · NCT05183035

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Indiana University/Riley Hospital for Children, Indianapolis
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT01351545

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

  • Community Health Network, Indianapolis
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 24. jun. 2026 · NCT04068597

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

  • Indiana University, Bloomington
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 18 til 120 · Alle kjønn · Oppdatert 25. jul. 2025 · NCT05237258

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.